Catheter-based closure of residual leaks after percutaneous occlusion of the left atrial appendage

Introduction The purpose of this study was to evaluate safety and efficacy of catheter‐based occlusion of residual leaks after percutaneous closure of the left atrial appendage (LAA). Methods All cases of LAA closure at our center were reviewed to identify secondary interventions for residual leaks....

Full description

Saved in:
Bibliographic Details
Published inCatheterization and cardiovascular interventions Vol. 87; no. 7; pp. 1324 - 1330
Main Authors Hornung, Marius, Gafoor, Sameer, Id, Dani, Vaskelyte, Laura, Hofmann, Ilona, Franke, Jennifer, Sievert, Horst, Bertog, Stefan C.
Format Journal Article
LanguageEnglish
Published United States Blackwell Publishing Ltd 01.06.2016
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Introduction The purpose of this study was to evaluate safety and efficacy of catheter‐based occlusion of residual leaks after percutaneous closure of the left atrial appendage (LAA). Methods All cases of LAA closure at our center were reviewed to identify secondary interventions for residual leaks. Leaks with a width of more than 3 mm by transesophageal echocardiography (TEE) were considered relevant. In a case‐specific approach, depending on the respective morphology of the defect, either an LAA occlusion device or an Amplatzer Vascular Plug was implanted under TEE and fluoroscopic guidance. Results Between June 2003 and December 2013, 12 patients underwent residual leak closure. All procedures were technically successful and without complications. In 10 cases (83%), complete sealing was confirmed at TEE follow‐up. In 2 patients, minimal gaps (2–3 mm) persisted and anticoagulation was continued. None of the patients had strokes during the follow‐up period. Conclusion Percutaneous residual leak closure after attempted LAA occlusion can be done safely and with high procedural success rates. © 2015 Wiley Periodicals, Inc.
Bibliography:ark:/67375/WNG-7FQZPSBD-B
istex:46EA6AF2BD5A60B73CB34333E87583CAD8CA3311
ArticleID:CCD26318
Conflict of interest? The authors’ institution has ownership interest in or has received consulting fees, travel expenses or study honoraries from the following companies: Abbott, Access Closure, AGA, Angiomed, Arstasis, Atritech, Atrium, Avinger, Bard, Boston Scientific, Bridgepoint, Cardiac Dimensions, CardioKinetix, CardioMEMS, Coherex, Contego, CSI, EndoCross, EndoTex, Epitek, Evalve, ev3, FlowCardia, Gore, Guidant, Guided Delivery Systems, Inc., InSeal Medical, Lumen Biomedical, HLT, Kensey Nash, Kyoto Medical, Lifetech, Lutonix, Medinol, Medtronic, NDC, NMT, OAS, Occlutech, Osprey, Ovalis, Pathway, PendraCare, Percardia, pfm Medical, Rox Medical, Sadra, SJM, Sorin, Spectranetics, SquareOne, Trireme, Trivascular, Velocimed, Veryan.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1522-1946
1522-726X
DOI:10.1002/ccd.26318